Massive Bio has announced its first strategic investment in another artificial intelligence company, backing healthcare AI infrastructure provider Rivvi AI to strengthen oncology clinical trial enrollment and patient engagement. Revealed at Ai4 2026, the investment expands Massive Bio’s strategy beyond developing AI-powered precision oncology solutions by supporting technologies that connect clinical intelligence with personalized patient outreach and care navigation.

Massive Bio, an AI-enabled precision oncology and real-world data company, has made its first strategic investment in Rivvi AI, an agentic AI infrastructure provider focused on healthcare and life sciences. While financial terms were not disclosed, the investment represents a broader move by Massive Bio to build an ecosystem of complementary AI technologies that improve patient engagement and accelerate clinical research.

The partnership builds on the companies’ existing collaboration across oncology clinical trial programs and aims to combine Massive Bio’s clinical intelligence platform with Rivvi’s conversational AI infrastructure. Together, the companies plan to streamline patient identification, outreach, navigation, and care coordination for complex healthcare workflows.

The announcement reflects a growing trend across healthcare technology, where artificial intelligence is increasingly being deployed not only to analyze medical data but also to automate operational processes that improve patient access to care and clinical research participation.

One of the biggest challenges facing oncology research remains patient enrollment. Complex eligibility requirements, fragmented patient records, limited staffing, and delayed outreach often prevent eligible patients from accessing potentially beneficial treatments.

Massive Bio’s technology focuses on solving the identification problem. Its neuro-symbolic, multi-agent AI platform structures clinical and biomarker data to match patients with suitable oncology trials. According to the company, its AI system was prospectively evaluated across more than 3,800 oncology patients, generating over 17,000 oncologist-confirmed trial matches while reducing matching time by four times compared with conventional workflows.

Rivvi AI addresses the next stage of the process by converting those patient matches into actionable workflows. Its AI agents automate patient communication, appointment coordination, consent management, barrier identification, and escalation to healthcare professionals when human intervention is required. The company says its platform has supported more than two million patient interactions across over 500,000 patients, serving healthcare providers, pharmacies, payers, and life sciences organizations.

The combined platform is structured around three operational layers. Massive Bio identifies eligible patients using clinical and biomarker intelligence, Rivvi AI manages personalized patient engagement through governed conversational workflows, and healthcare professionals complete referrals, screenings, and treatment decisions while maintaining full clinical oversight.

Importantly, the companies emphasize that the AI platform is designed to support, not replace, clinical decision-making. Rivvi’s technology does not diagnose diseases or recommend treatments. Instead, it automates administrative and communication tasks while preserving human review, organizational policies, audit trails, and compliance controls.

Governance has become an increasingly important differentiator as healthcare organizations expand enterprise AI adoption. Rivvi’s platform is HIPAA compliant and SOC 2 Type II certified, allowing health systems and life sciences organizations to deploy AI-powered workflows without requiring new electronic medical record integrations.

The collaboration also reflects a broader evolution in enterprise AI strategy. Rather than building every capability internally, technology companies are increasingly investing in specialized AI providers whose platforms complement their existing products. Similar ecosystem-driven approaches have been adopted across enterprise technology by companies including Microsoft, Google, Amazon, Salesforce, and Adobe, all of which continue expanding AI capabilities through strategic partnerships and acquisitions.

For pharmaceutical companies, biotechnology firms, hospitals, and healthcare providers, the combined platform could improve patient recruitment for clinical trials while supporting medication adherence, care-gap closure, appointment scheduling, and long-term patient engagement. The modular architecture also allows organizations to deploy AI-powered workflows without replacing existing clinical systems.

For Massive Bio, the investment represents more than a financial transaction. It establishes a repeatable investment model through which the company can selectively support AI startups that strengthen different stages of the patient journey. By combining clinical evidence, oncology expertise, AI infrastructure, and strategic capital, Massive Bio aims to accelerate the adoption of enterprise-grade healthcare AI that improves both clinical research and patient outcomes.

As healthcare organizations continue investing in AI-enabled digital transformation, partnerships that combine clinical intelligence with operational automation are likely to play an increasingly important role in making precision medicine more scalable, accessible, and efficient.

Top Insights

  • Massive Bio has made its first strategic AI investment, backing Rivvi AI to strengthen oncology patient engagement and clinical trial recruitment.
  • The partnership combines AI-powered patient-trial matching with conversational AI workflows that automate outreach, scheduling, and care coordination.
  • Massive Bio’s AI platform has demonstrated faster clinical trial matching, while Rivvi has supported more than two million patient interactions.
  • The integrated platform maintains human oversight, audit trails, and compliance controls, supporting enterprise healthcare governance requirements.
  • The investment reflects growing enterprise demand for interoperable AI ecosystems that connect clinical intelligence with operational healthcare automation.

Have a story or business inquiry?Contact our FinTechEdition team today.

Source: Massive Bio